CARING: CARbon Impact of aNesthesic Gas
Study Details
Study Description
Brief Summary
Assessing the impact of anesthesia practice on global warming and carbon footprint becomes part of the standard of care and is growing concern within the anesthesia community. Global Warming Potential (GWP) is a measure of how much a given mass of greenhouse gas contributes to global warming over a specified time period. Inhaled anesthetics have various GWP20: 349 for sevoflurane and 3714 for desflurane. However, GWP20 and CDE20 alone are not sufficient to evaluate the environmental impact of anesthetic gases. Other parameters must be included in the analysis: fresh gas flow (FGF), carrier gas (air, O2, N2O) and potency of the anesthetic gas. Unfortunately, the majority of trials did not fully consider the FGF reduction and the fact that desflurane can be administered with new closed or very low-flow anesthesia circuits as opposed as the recommended 2L/min that must be used for sevoflurane according to its monography in Canada. Most of the calculations were made on a purely theoretical approach that could be different from actual measurements based on a strictly monitored anesthesia practice. When continuous and accurate gas monitoring and analysis is used as recommended nowadays, the use of closed or semi-closed-circuit anesthesia with very low FGF might allow for a reduction of more than 80% of the anesthetic gas administration and its consequent pollution. By properly monitoring the anesthesia depth and analgesia adequacy, the investigators can reduce the gas consumption. The proposed study will aim at determining whether with the help of high-quality monitoring (BIS and NOL) and high-end ventilators that allow minimal fresh gas flow, the use of desflurane remains more polluting than sevoflurane.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Desflurane desflurane administration based on a BIS index kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator and its econometer for an optimized fresh gas flow as low as the O2 consumption allows |
Other: Pollution
CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
|
| Sevoflurane sevoflurane administration based on a BIS kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator with a fixed fresh gas flow of 2L/min as requested in the gas monography |
Other: Pollution
CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
|
Outcome Measures
Primary Outcome Measures
- CO2 equivalent of volatile inhaled anesthesic gases use in grams [From intubation to end of surgery]
To compare total volatile inhaled anesthetics consumption in CO2 equivalent (grams) per hour during anesthesia for laparoscopic surgery between two groups: Group "D" for Desflurane and group "S" for Sevoflurane
Secondary Outcome Measures
- Total volatile inhalated anesthesics consumption in mL [From intubation to end of surgery]
To compare the total volatile inhaled anesthetics consumption in mL, mL/h and mL/kg/h during anesthesia for laparoscopic surgery between desflurane and sevoflurane
- Cost in dollars [From intubation to end of surgery]
To compare the total cost of volatile inhalated anesthesics (mL of gaz x $/mL of gaz) for each group
- Extubation time in minutes [From stopping anesthesics gases to extubation]
To compare the extubation time
- Recovery room time in minutes [From end of surgery to 240minutes post-surgery]
To compare the time spent in the recovery room
Eligibility Criteria
Criteria
Inclusion Criteria:
-
ASA 1-3 patients,
-
laparoscopic general, gynecological or urologic surgery requiring general anesthesia without additional regional anesthesia technique
-
fully consented,
-
BMI < 40,
-
age > 18yo,
Exclusion Criteria:
-
post-operative need for a neuraxial or regional analgesic technique
-
history of active coronary artery disease
-
serious cardiac arrhythmia (including atrial fibrillation)
-
history of substance abuse
-
chronic use of psychotropic and/or opioid drugs
-
history of psychiatric diseases with the need of medication
-
history of refractory PONV
-
allergy or contra-indication to any drug used in the study protocol
-
refusal of the patient for participation in the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal | Montréal | Quebec | Canada | H1T2M4 |
Sponsors and Collaborators
- Ciusss de L'Est de l'Île de Montréal
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020-1971